Yet another collaboration with a giant pharmaceutical company for Hemogenyx Pharmaceuticals?
“…When we get into clinical trials we achieve an inflexion point for Hemogenyx and the price of our shares will follow…”
What is not under any doubt is that Hemogenyx Pharmaceuticals is developing breakthrough therapies for the treatment of blood diseases, and the company is confident an IND will be opened on its HEMO-CAR-T treatment of Acute Myeloid Leukemia by the end of this year.
‘IND’ is an acronym for Investigational New Drug which is a drug that is ready for clinical trials on humans. Another acronym applicable to the #HEMO story is ‘IGC’ or ‘it’s getting closer.’
Rewind 12 months when the stock surged 260% after the company announced it was using its advanced humanised mice to develop potential treatments for COVID-19. At the time the company said: “Although Hemogenyx has not traditionally been focused on fighting infectious diseases, we have always been focused on saving lives. In light of the current COVID-19 pandemic, we are determined to use our proprietary technology, expertise and resources to save lives and alleviate suffering.”
It’s proof that Hemogenyx is not a ‘one trick pony, but the word ‘suffering’ is poignant because as a major shareholder, co-founder and Chief Executive Dr Vladislav Sandler, experiences the pain of share price movements when they are not in the ascendancy. And the share price has been responding to events that are not related to the strides being made towards company-making inflexion points.
That of funder Mint Capital’s enthusiasm for convertible loan note conversions in respect of approximately £950,000 not once, but three times this year, and just months after #HEMO agreed a £60 million financing facility with the investment management company.
The sum was needed to progress the multi-stranded pipeline that has engaged the likes of Eli Lilly, global pharmaceutical company GlobalCo, the University of Pennsylvania. The funds were intended to give #HEMO greater choice in determining what strategic partnerships to pursue and on what terms.
The irony is that it’s the relationship with Mint Capital, and its perceived impatience, which is stealing the headlines and suppressing the investment value enhancing narrative as outlined by Sandler in this podcast with Sarah Lowther.
The Prospectus for Mint Capital’s investment in #HEMO can be viewed here.
Click here to read the latest broker research note.
The author was remunerated but does not hold shares in the company
